All In Biotech

Drug Trial Radar · NCT06291207

A Study to Evaluate the Efficacy and Safety of AD-224

A Randomization, Double-blind, Active-controlled, Multicenter, Phase 3 Trial to Evaluate the Efficacy and Safety of AD-224A and AD-224B in Patients With Essential Hypertension

Last checked: Nov 19, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 254 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

254

Actual

Start

Apr 15, 2024

Primary completion

Apr 7, 2025

Study completion Apr 7, 2025

Sponsor

Lead sponsor
Addpharma Inc.Industry
Sponsor type
Industry
First posted
Mar 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of AD-224

Conditions

  • Hypertension,Essential

Interventions

  • AD-224ADrug

    PO, Once daily, 8weeks

  • AD-224BDrug

    PO, Once daily, 8weeks

  • AD-224CDrug

    PO, Once daily, 8weeks

  • Placebo of AD-224ADrug

    PO, Once daily, 8weeks

  • Placebo of AD-224BDrug

    PO, Once daily, 8weeks

  • Placebo of AD-224CDrug

    PO, Once daily, 8weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change rate of MSSBPTime frame: Baseline, Week 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Seoul National University Bundang Hospital

    Seongnam-si, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.